Super-Potent class 1 efficacy1,2

For patients who require a hydrating lotion formulation3

ULTRAVATE® Lotion (halobetasol propionate, 0.05%) provides the hydrating benefits of a cream3

Proven hydration vs a cream formulation3

Significantly greater skin surface hydration vs a cream up to 4 hours post-application
Matches the hydration of a cream at 6 hours post-application

In the same adult study, ULTRAVATE® Lotion demonstrated no statistically significant differences in transepidermal water loss compared to a cream formulation.3

Formulated with hydrating emollients to increase and maintain skin moisturization1,3

ULTRAVATE® Lotion ingredients1:

  • Halobetasol propionate, 0.05%
  • Diisopropyl adipate
  • Octyldodecanol
  • Ceteth-20
  • Poloxamer 407
  • Cetyl alcohol
  • Stearyl alcohol
  • Propylparaben
  • Butylparaben
  • Propylene glycol
  • Glycerin
  • Carbomer homopolymer
  • Sodium hydroxide
  • Water
See Tolerability Data
References: 1. ULTRAVATE® Lotion [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2017. 2. National Psoriasis Foundation. Topical steroid potency chart. potency-chart. Accessed October 31, 2019. 3. Grove G, Zerweck C, Houser T, et al. Occlusivity and moisturization potential of a new lotion formulation of halobetasol propionate, 0.05%. Poster presented at: 74th Annual Meeting of the American Academy of Dermatology; March 4-8, 2016; Washington, DC.

ULTRAVATE (halobetasol propionate) Lotion is a corticosteroid indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older.


Usage: Limit use to 50 g/week. Discontinue treatment when control is achieved. If no improvement is seen within 2 weeks, reassess diagnosis. Treatment beyond 2 consecutive weeks is not recommended. Avoid use on the face, scalp, groin, or axillae.

Effects on Endocrine System: Reversible hypothalamic-pituitary-adrenal (HPA) axis suppression may occur, with the potential for glucocorticosteroid insufficiency during or after treatment. Systemic effects of topical corticosteroids may also include Cushing’s syndrome, hyperglycemia, and glucosuria. Systemic absorption may require evaluation for HPA axis suppression. Use of potent corticosteroids on large areas, for prolonged durations, under occlusive dressings, or on an altered skin barrier may increase systemic exposure. Children may be more susceptible to systemic toxicity when treated with topical steroids.

Local Adverse Reactions: Local adverse reactions with topical steroids may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection and miliaria. These may be more likely to occur with occlusive use, prolonged use or more potent corticosteroids, including ULTRAVATE.

Concomitant Skin Infections: Use an appropriate antimicrobial agent if a skin infection is present or develops.

Allergic Contact Dermatitis: Discontinue ULTRAVATE Lotion if allergic contact dermatitis is established.

In clinical trials the most common adverse reactions (≥1%) were telangiectasia, application site atrophy, and headache.

To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-800-406-7984 or FDA at 1-800-FDA-1088 or

Please see Full Prescribing Information for complete prescribing details.